Based on the AstraZeneca PLC stock forecast from 0 analysts, the average analyst target price for AstraZeneca PLC is not available over the next 12 months. AstraZeneca PLC’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of AstraZeneca PLC is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, AstraZeneca PLC’s stock price was USD 132.65. AstraZeneca PLC’s stock price has changed by +0.69% over the past week, +5.70% over the past month and +1.65% over the last year.
No recent analyst target price found for AstraZeneca PLC
No recent average analyst rating found for AstraZeneca PLC
Company Overview AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Read Less
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga...Read More
Frequently Asked Questions About AstraZeneca PLC (AZNCF) Stock
Stock Target Advisor's fundamental analysis for AstraZeneca PLC's stock is Slightly Bullish .
AZNCF stock's dividend yield is 2.27%.
Our analysis grades AZNCF stock's dividend yield at F. This means that AZNCF stock's dividend yield is above 25% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this AZNCF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on AZNCF's stock to indicate what its average analyst target is.
AZNCF stock's Price/Earning ratio is 31.74.
Our analysis grades AZNCF stock's Price / Earning ratio at F. This means that AZNCF stock's Price/Earning ratio is above 71% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this AZNCF may be a overvalued for its sector.
The last closing price of AZNCF's stock was USD 132.65.
The most recent market capitalization for AZNCF is USD 209.14B.
Unfortunately we do not have enough analyst data on AZNCF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AstraZeneca PLC's stock.
As per our most recent records AstraZeneca PLC has 89,900 Employees.
AstraZeneca PLC's registered address is 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA.
You can get more information about it from AstraZeneca PLC's website at https://www.astrazeneca.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About AstraZeneca PLC (AZNCF) Stock
Stock Target Advisor's fundamental analysis for AstraZeneca PLC's stock is Slightly Bullish .
AZNCF stock's dividend yield is 2.27%.
Our analysis grades AZNCF stock's dividend yield at F. This means that AZNCF stock's dividend yield is above 25% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this AZNCF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on AZNCF's stock to indicate what its average analyst target is.
AZNCF stock's Price/Earning ratio is 31.74.
Our analysis grades AZNCF stock's Price / Earning ratio at F. This means that AZNCF stock's Price/Earning ratio is above 71% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this AZNCF may be a overvalued for its sector.
The last closing price of AZNCF's stock was USD 132.65.
The most recent market capitalization for AZNCF is USD 209.14B.
Unfortunately we do not have enough analyst data on AZNCF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AstraZeneca PLC's stock.
As per our most recent records AstraZeneca PLC has 89,900 Employees.
AstraZeneca PLC's registered address is 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA.
You can get more information about it from AstraZeneca PLC's website at https://www.astrazeneca.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AZNCF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
